ASCO GU Symposium 2021

In-depth coverage of the 2021 ASCO GU Symposium

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021

Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 10, 2023

The phase 3 CLEAR trial showed improved OS for lenvatinib plus pembrolizumab as first-line therapy for advanced RCC.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021

Nivolumab improves disease-free survival, non-urothelial tract recurrence-free survival, and metastasis-free survival.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | August 23, 2023

The phase 2 SWOG 1500 trial showed improvement in progression-free survival for cabozantinib in metastatic papillary RCC.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | May 7, 2023

Relugolix represents a new oral option for GnRH receptor antagonism.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | December 2, 2022

Establishing Cabazitaxel as third-line therapy for metastatic castration-resistant prostate cancer by the phase 4 CARD trial.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | February 22, 2021

177Lu-PSMA-617 was able to generate more PSA responses of at least 50% reduction compared to taxane cabazitaxel in mCRPC.

Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | October 12, 2023

Adding enzalutamide to androgen deprivation therapy improved progression-free survival in hormone-sensitive prostate cancer.